ÂÜÀòÂÒÂ×

Stefan Bissinger has a broad range of work experience, beginning in 2007 with an internship at Bavarian Nordic GmbH. In 2008, they completed an internship at Statens veterinärmedicinska anstalt, SVA, and in 2009 they completed a Diploma Thesis at Roche. In 2010, they worked as an Engineer Analytical Services BU Beverages at Symrise AG. From 2012 to 2018, they worked at Roche in various roles, including Postdoc, PhD Student, and Senior Scientist. Since 2018, they have been the Director Preclinical Pharmacology & Biomarker Development at iOmx Therapeutics AG, where they have also held the roles of Associate Director and Principal Scientist. In these roles, they have been responsible for leading the department of Preclinical Pharmacology & Biomarker Development, driving the development of iOmx's lead small and large molecule projects until IND, and guiding pre-clinical and clinical development of drug candidates. Stefan has also been responsible for execution of preclinical in vivo pharmacology experiments, RNA and protein-based target expression analysis, and discovery of iOmx's anti-IGSF11 cancer-immunotherapy antibody program.

Stefan Bissinger obtained their Allgemeine Hochschulreife from Theodor Heuss Gymnasium, Nördlingen between 1996 and 2005, with advanced courses in mathematics and biology. Stefan then attended the University of Applied Sciences Weihenstephan-Triesdorf, where they received their Diplom-Ingenieur in biotechnology between 2005 and 2010. Finally, they attended FAU Erlangen-Nürnberg, where they obtained their doctor rerum naturalium (Dr. rer. nat) - PhD between 2013 and 2017.